Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Cell Rejuvenation Therapy for Age-related Macular Degeneration

Objective

Age-related macular degeneration (AMD) is a leading cause for blindness, resulting in loss of vision at the center of the visual field - the macula, due to damage to the retina. The disease, usually affecting older adults (>55), was diagnosed in 2020 in 196 million people worldwide, with an estimated economic toll of $343 billion including $255 billion in direct healthcare costs. In AMD, photoreceptors and retinal pigmented epithelium (RPE) cells which underlie the photoreceptors undergo degeneration. The standard care is injections of anti-VEGF medicines such as ranibizumab (Lucentis), aflibercept (Eylea) and brolucizumab (Beovu) to the eye every 1-3 months. These delay disease progress but cannot restore lost vision, and have side effects such as bleeding in the eye. During an ERC Starting project, the PI has discovered a new method that would allow to not only delay the disease but to also improve RPE cells function as a treatment for AMD. The proposed approach to rescue RPE cells is rejuvenation by a technique called partial reprogramming. Our results suggest that the proposed technique is safe and efficient in rejuvenating mouse and human fibroblasts, and in improving their function. In the current application, through in vivo studies, we will prepare for implementing our novel approach in our envisioned product I-SEE. In I-SEE, we will aim to use our discovery of a unique combination of factors, that successfully reprogram cells, to drive aging RPE cells into rejuvenation and improved function. We will calibrate the expression of the reprogramming factors in RPE cells, and test rejuvenation and improved function in AMD mouse models. IPR and partnering with clinician and industry will be developed concomitantly. Our final product, I-SEE, is developed based on a PCT patent Application No. 63/210,030, as a cocktail of molecules of mRNA directly applied to the eye, to offer the first AMD treatment that could restore vision.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2022-POC1

See all projects funded under this call

Host institution

THE HEBREW UNIVERSITY OF JERUSALEM
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 150 000,00
Address
EDMOND J SAFRA CAMPUS GIVAT RAM
91904 JERUSALEM
Israel

See on map

Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Beneficiaries (1)

My booklet 0 0